Breast cancer survivorship continues to rise, but the long-lasting psychosocial and quality-of-life changes that occur after treatment need to be studied, as treatment outcomes can lead to negative side effects that outlast the treatment. More »
This article provides a comprehensive summary of the knowledge gained from recent neoadjuvant trials conducted with agents targeting HER2, and will put them into perspective with current treatment recommendations from American and European guidelines. More »
It may not be appropriate, nor always considered standard, to recommend neoadjuvant chemotherapy for all patients for whom adjuvant therapy was recommended before surgery. Indeed, tumor size and nodal status play a role, as do hormone receptors, in determining the appropriate extent of adjuvant... More »
Bevacizumab (Avastin) improved progression-free survival (PFS) in women with HER2-positive locally recurrent or metastatic breast cancer by an average of 3 months when added to standard treatment as first-line therapy in the multinational, randomized, phase III AVEREL study. More »
Had the 1986 Forrest Report – which led to widespread mammography screening in Great Britain – included the harms of screening for breast cancer, it might never have become standard practice, according to a new British Medical Journal report. The American College of Radiology (ACR) promptly... More »
Addition of pertuzumab to a standard chemotherapy combination of trastuzumab and docetaxel led to a 38% reduction in risk of disease worsening or death in patients with HER2-positive metastatic breast cancer, reported investigators from the randomized, double-blind, placebo-controlled phase III... More »
Magnetic resonance imaging’s accuracy in detecting cancer in the lymph nodes of newly diagnosed breast cancer patients is nothing to sniff at – 80 percent with diffusion-weighted MRI and 85 percent with axial T1-weighted MRI, Canadian researchers have reported. But it’s not quite high enough to skip... More »
CHICAGO — Women in their 40s without a family history of the disease face the same risk for breast cancer and should be screened, according to a study released at RNSA Tuesday. More »
Is estrogen plus progestin better than estrogen alone for symptom relief in menopausal women? For women who have not had a hysterectomy, adding progestin to estrogen therapy counteracts the increased risk of uterine cancer from estrogen monotherapy. However, the progestin and estrogen combination... More »
CHICAGO — Carol Lee, MD, a Memorial Sloan-Kettering Cancer Center radiologist, presented a balanced menu of evidence on breast-cancer screening at RSNA 2011 on Monday. She offered up a slew of studies that, collectively, have found mammography to cut breast cancer mortality around 25 percent. She... More »
In this four-minute video interview conducted at RSNA 2011, Dr Berg reviews new data from the ACRIN 6666 study that suggests operator error is similar for all of the major imaging techniques employed for breast cancer detection.
Approved by the FDA February 11, 2011, breast tomosynthesis, a new imaging technology pioneered by the MGH Breast Imaging Program under the leadership of Elizabeth Rafferty, MD, director of Breast Imaging at MGH, produces a 3D image of the breast and gives doctors a clearer view through the overlapping structures of breast tissue.
GE's Senograph mammography systems, magnetic resonance systems, logic ultrasound system and molecular breast imaging offer new possibilities for noninvasive breast cancer detection...
The more advanced and more complicated the disease process, the more likely the patient will end up with surgery and/or amputation, increasing the cost of initial care and the additional intervention.
If those of us who are in positions to evaluate and review hiring policies do not take a significant role in ensuring a level playing field then we are truly to blame.
Tax Schemes Every Physician Should Avoid Ike Devji, JD, January 31, 2012 The next 60 days marks the final push to sell physicians across the United States tax plans of both good and questionable value.
Prevent Physician Distraction When Using mHealth Technology Aubrey Westgate, January 25, 2012 As more and more physicians use handheld mobile technology in their day-to-day work, some critics are raising concerns about “distracted doctoring.”
Can That Applicant Do the Job at Your Medical Practice? Karen Zupko, January 25, 2012 If like many communities, yours has significant numbers of non-English speaking people with whom neither you nor your staff are able to converse, your practice is at a serious disadvantage.
